≡

Complement Component 5a Receptor 1 (C5aR1)

[Edit]

CD88; C5A; C5-AR1; C5R1; C5a anaphylatoxin chemotactic receptor 1

Complement Component 5a Receptor 1 (C5aR1)
CCC B308
HGNC 1338
MGI 88232
PubMed 10636859
RGD 70553
UniProt P21730
Wiki C5a_receptor

The C5a receptor is a G protein-coupled receptor for C5a. It functions as a complement receptor.Rittirsch et al. (2008) used mice lacking C5ar or C5l2 (GPR77) or antibody-induced blockade of C5ar and C5l2 to investigate the roles of C5a receptors in sepsis induced by cecal ligation and puncture. They observed increased survival and attenuation of plasma proinflammatory mediator production in mid-grade sepsis when either receptor was blocked or absent. Expression of Hmgb1 , a key late mediator in sepsis, was dependent on C5l2, but not C5ar. In high-grade sepsis, only combined blockade of both C5ar and C5l2 afforded protection. Rittirsch et al. (2008) proposed that C5AR and C5L2 contribute synergistically to the harmful consequences in sepsis and that C5L2 is required for HMGB1 release.

Organism species: Homo sapiens (Human)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins CPB308Hu21 OVA Conjugated Complement Component 5a Receptor 1 (C5aR1) Immunogen; SDS-PAGE; WB.
Antibodies n/a Monoclonal Antibody to Complement Component 5a Receptor 1 (C5aR1) Monoclonal Antibody Customized Service Offer
n/a Polyclonal Antibody to Complement Component 5a Receptor 1 (C5aR1) Polyclonal Antibody Customized Service Offer
Assay Kits SEB308Hu ELISA Kit for Complement Component 5a Receptor 1 (C5aR1) Enzyme-linked immunosorbent assay for Antigen Detection.
CEB308Hu ELISA Kit for Complement Component 5a Receptor 1 (C5aR1) Enzyme-linked immunosorbent assay for Antigen Detection.

Organism species: Mus musculus (Mouse)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins RPB308Mu01 Recombinant Complement Component 5a Receptor 1 (C5aR1) Positive Control; Immunogen; SDS-PAGE; WB.
RPB308Mu02 Recombinant Complement Component 5a Receptor 1 (C5aR1) Positive Control; Immunogen; SDS-PAGE; WB.
Antibodies PAB308Mu01 Polyclonal Antibody to Complement Component 5a Receptor 1 (C5aR1) WB; IHC; ICC; IP.
PAB308Mu02 Polyclonal Antibody to Complement Component 5a Receptor 1 (C5aR1) WB; IHC; ICC; IP.
Assay Kits SEB308Mu ELISA Kit for Complement Component 5a Receptor 1 (C5aR1) Enzyme-linked immunosorbent assay for Antigen Detection.

Organism species: Rattus norvegicus (Rat)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins n/a Recombinant Complement Component 5a Receptor 1 (C5aR1) Recombinant Protein Customized Service Offer
Antibodies n/a Monoclonal Antibody to Complement Component 5a Receptor 1 (C5aR1) Monoclonal Antibody Customized Service Offer
n/a Polyclonal Antibody to Complement Component 5a Receptor 1 (C5aR1) Polyclonal Antibody Customized Service Offer
Assay Kits n/a CLIA Kit for Complement Component 5a Receptor 1 (C5aR1) CLIA Kit Customized Service Offer
n/a ELISA Kit for Complement Component 5a Receptor 1 (C5aR1) ELISA Kit Customized Service Offer
  1. "Expression cloning of a receptor for C5a anaphylatoxin on differentiated HL-60 cells."Biochemistry 30:2993-2999(1991) [PubMed] [Europe PMC] [Abstract]
  2. "The chemotactic receptor for human C5a anaphylatoxin."Nature 349:614-617(1991) [PubMed] [Europe PMC] [Abstract]
  3. "The DNA sequence and biology of human chromosome 19." Nature 428:529-535(2004) [PubMed] [Europe PMC] [Abstract]
  4. "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)."Genome Res. 14:2121-2127(2004) [PubMed] [Europe PMC] [Abstract]
  5. "Human chemotaxis receptor genes cluster at 19q13.3-13.4. Characterization of the human C5a receptor gene."Biochemistry 32:1243-1250(1993) [PubMed] [Europe PMC] [Abstract]
  6. "The amino terminus of the human C5a receptor is required for high affinity C5a binding and for receptor activation by C5a but not C5a analogs."J. Biol. Chem. 269:14446-14450(1994) [PubMed] [Europe PMC] [Abstract]
  7. "Mutation of glutamate 199 of the human C5a receptor defines a binding site for ligand distinct from the receptor N terminus."J. Biol. Chem. 270:16625-16629(1995) [PubMed] [Europe PMC] [Abstract]
  8. "Identification of the major phosphorylation sites in human C5a anaphylatoxin receptor in vivo."J. Biol. Chem. 270:19166-19172(1995) [PubMed] [Europe PMC] [Abstract]
  9. "Residues 21-30 within the extracellular N-terminal region of the C5a receptor represent a binding domain for the C5a anaphylatoxin."J. Biol. Chem. 273:10411-10419(1998) [PubMed] [Europe PMC] [Abstract]
  10. "Human complement 5a (C5a) anaphylatoxin receptor (CD88) phosphorylation sites and their specific role in receptor phosphorylation and attenuation of G protein-mediated responses. Desensitization of C5a receptor controls superoxide production but not receptor sequestration in HL-60 cells."J. Biol. Chem. 275:1656-1664(2000) [PubMed] [Europe PMC] [Abstract]
  11. "Sulfated tyrosines contribute to the formation of the c5a docking site of the human c5a anaphylatoxin receptor."J. Exp. Med. 193:1059-1066(2001) [PubMed] [Europe PMC] [Abstract]
  12. "Phosphorylation of key serine residues is required for internalization of the complement 5a (C5a) anaphylatoxin receptor via a beta-arrestin, dynamin, and clathrin-dependent pathway."J. Biol. Chem. 278:4277-4285(2003) [PubMed] [Europe PMC] [Abstract]
  13. "C5a receptor oligomerization. I. Disulfide trapping reveals oligomers and potential contact surfaces in a G protein-coupled receptor."J. Biol. Chem. 278:35345-35353(2003) [PubMed] [Europe PMC] [Abstract]
  14. "Chemotaxis inhibitory protein of Staphylococcus aureus binds specifically to the C5a and formylated peptide receptor."J. Immunol. 172:6994-7001(2004) [PubMed] [Europe PMC] [Abstract]
  15. "Residues 10-18 within the C5a receptor N terminus compose a binding domain for chemotaxis inhibitory protein of Staphylococcus aureus."J. Biol. Chem. 280:2020-2027(2005) [PubMed] [Europe PMC] [Abstract]
  16. "Tyrosine sulfation in N-terminal domain of human C5a receptor is necessary for binding of chemotaxis inhibitory protein of Staphylococcus aureus."Acta Pharmacol. Sin. 32:1038-1044(2011) [PubMed] [Europe PMC] [Abstract]